Regulatory Insider Filing: Francis Sarena Sold 34654 shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in an Insider Trade

November 29, 2016 - By whatsonthorold

Regulatory Insider Filing: Francis Sarena Sold 34654 shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in an Insider Trade

Francis Sarena Insider Sell

Francis Sarena, Chief Strategy Officer of Five Prime Therapeutics Inc is the insider, our financial writers want to inform you for. Mr. Francis submitted a form with the Washington-based Security and Exchange Commission revealing a sale for 34,654 shares of the firm, the one he is an insider in. At the time of the selling transaction, the average market share price of Five Prime Therapeutics Inc was $60.4, making the sale worth $2,092,508 U.S Dollars. The probability of this stocks unloading staying unseen is very little due to its amount, with the Chief Strategy Officer today having rights to 81,266 shares – that is 0.31% of the total market capitalization of Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $52 is the highest target while $33 is the lowest. The $45.75 average target is -21.97% below today’s ($58.63) stock price. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Credit Suisse initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Thursday, January 21 with “Outperform” rating. The rating was initiated by Citigroup on Friday, July 31 with “Buy”. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Sell” rating given on Friday, August 21 by Zacks. Credit Suisse maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, March 11 with “Outperform” rating. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The firm has “Outperform” rating given on Monday, October 19 by Oppenheimer. The firm has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets. The stock has “Buy” rating given by Citigroup on Tuesday, October 25. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Sell” rating by Zacks on Tuesday, August 11.

Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 1.14, from 2.29 in 2016Q1. The ratio fall, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.

Ajo Limited Partnership accumulated 0.03% or 188,140 shares. The Pennsylvania-based Pnc Fin Services Grp Inc Inc has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Fifth Third Bank has 0% invested in the company for 300 shares. Ny State Teachers Retirement accumulated 2,000 shares or 0% of the stock. Schroder Invest Mgmt Gru holds 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 15,198 shares. Metropolitan Life New York holds 0.01% or 19,875 shares in its portfolio. Parametric Portfolio Assocs Ltd holds 0% or 43,765 shares in its portfolio. Moreover, Numeric Invsts Ltd Liability Com has 0.08% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 222,846 shares. Northern Tru has 0% invested in the company for 324,934 shares. Da Davidson And accumulated 3,203 shares or 0% of the stock. Connor Clark Lunn Management Limited accumulated 0.01% or 32,925 shares. The New York-based Spark Inv Management Ltd Liability has invested 0.57% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Doheny Asset Management Ca accumulated 6,150 shares or 0.13% of the stock. First Trust Advsr Lp, a Illinois-based fund reported 41,250 shares. Envestnet Asset Management last reported 1,047 shares in the company.

Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 6 selling transactions for $1.15 million net activity. Shares for $449,589 were sold by Jensen Peder on Wednesday, November 9. On Tuesday, November 1 the insider RINGO WILLIAM R sold $24,335.

The stock decreased 3.70% or $2.26 during the last trading session, hitting $58.63. About 290,526 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 31.09% since April 25, 2016 and is uptrending. It has outperformed by 25.07% the S&P500.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has a market cap of $1.68 billion. The Firm has three product candidates in clinical development covering multiple potential indications. It has a 7.63 P/E ratio. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on March, 9. They expect $-0.51 earnings per share, down 104.80% or $11.14 from last year’s $10.63 per share. After $-0.72 actual earnings per share reported by Five Prime Therapeutics Inc for the previous quarter, Wall Street now forecasts -29.17% EPS growth.

More news for Five Prime Therapeutics Inc (NASDAQ:FPRX) were recently published by: Globenewswire.com, which released: “Five Prime Therapeutics to Announce Third Quarter 2016 Financial Results and ..” on October 20, 2016. Benzinga.com‘s article titled: “Citi Launches Positive Coverage On Five Prime Therapeutics” and published on October 25, 2016 is yet another important article.

FPRX Company Profile

Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>